Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloid leukaemia (AML).